Company intelligence / Profile preview

ACSO

Ownership: Private
Development stage: Other

Overview

ACS Biotech develops innovative regenerative medicine solutions using chitosan biomaterials and cell therapy, with a primary focus on repairing articular cartilage damage. Their flagship product aims to restore mobility after knee injuries or osteoarthritis through minimally invasive surgery. Clinical results are not yet published, indicating pre-commercial status.

Therapeutic areas: Rheumatology
Modalities: Cell therapyBiomaterial-based therapy (Chitosan-based products)
Industry: Biotech

Beyond the preview

Go deeper on ACSO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACSO.

Explore the full profile